Back to results

Prevention of Alzheimer's Disease With CR Plus tDCS in Mild Cognitive Impairment and Depression (PACt-MD) (PACt-MD)

Primary Purpose

Mild Cognitive Impairment, Major Depressive Disorder, Recurrent, In Remission, Major Depressive Disorder, Single Episode, in Full Remission

Status

Unknown status

Phase

Not Applicable

Locations

Canada

Study Type

Interventional

Intervention

tDCS + CR

sham tDCS + sham CR

About this trial

This is an interventional prevention trial for Mild Cognitive Impairment

Eligibility Criteria

60 Years - undefined (Adult, Older Adult)All SexesAccepts Healthy Volunteers

MCI Group

Inclusion:

Age > 60 (on day of randomization)
DSM 5 criteria for Mild Neurocognitive Disorder ("MCI")
Willingness to provide informed consent
MADRS score of 10 or below
Availability of a study partner who has regular contact with the participant
Ability to read and communicate in English (with corrected vision and hearing, if needed)

Exclusion:

Met DSM 5 criteria for Major Depressive Episode in past 10 years
Lifetime DSM 5 diagnosis of schizophrenia, bipolar disorder, or OCD
DSM 5 diagnosis of alcohol or other substances use disorder within the past 12 months
High risk for suicide
Significant neurological condition (e.g., stroke, seizure disorder, MS)
Unstable medical illness, (e.g., uncontrolled diabetes mellitus or hypertension)
Having taken a cognitive enhancer (acetylcholinesterase inhibitor or memantine) within the past 6 weeks.
Participants taking anticonvulsants, and other psychotropic medication (see exceptions below) that cannot be safely tapered and discontinued. The following psychotropic medications are allowed: i) any antidepressant; ii) zopiclone, trazadone, or a benzodiazepine if they have been taken at a stable dose for at least 4 weeks prior to study entry and; iii) gabapentin and pregabalin if they have been taken at a stable dose for at least 4 weeks prior to study entry AND if prescribed for chronic pain.
A pace-maker or other metal implants that would preclude safe use of tDCS.

MDD Group

Inclusion:

Age ≥ 65 (on day of randomization)
Meets DSM 5 criteria for one or more MDE(s)with:
1. an offset of 2 months to 5 years from the screening visit date. It is not necessary for this (these) episode(s) to have received medical attention OR
2. an offset of 5 years or more from the screening visit date. It is necessary that at least one MDE received medical attention (e.g., previously been on one or more antidepressant(s), saw a psychiatrist, primary care physician, or had a previous hospitalization). Also, the MDE must have occurred during the participant's adult life (i.e., at 18 years of age or older).
MADRS score of 10 or below
Willingness to provide informed consent
Availability of a study partner who has regular contact with the participant
Ability to read and communicate in English (with corrected vision and hearing, if needed)

Exclusion:

Meets DSM 5 criteria for Major Neurocognitive Disorder ("dementia")
Lifetime DSM 5 diagnosis of schizophrenia, bipolar disorder, or OCD
DSM 5 diagnosis of alcohol or other substances use disorder within the past 12 months.
High risk for suicide.
Significant neurological condition (e.g., stroke, seizure disorder, MS)
Unstable medical illness (e.g., uncontrolled diabetes mellitus or hypertension)
Participants taking anticonvulsants, and other psychotropic medication (see exception below) that cannot be safely tapered and discontinued. In addition to any antidepressant, the following psychotropic medications are allowed if they have been taken at a stable dose for at least 4 weeks prior to study entry: zopiclone, trazodone, or a benzodiazepine; and gabapentin or pregabalin if prescribed for chronic pain.
Having taken a cognitive enhancer (acetylcholinesterase inhibitor or memantine) within the past 6 weeks.
A pace-maker or other metal implants that would preclude safe use of tDCS.
Received electroconvulsive therapy (ECT) within 6 months of baseline neruopsychological testing.

Control group

Inclusion:

Age > 60
MADRS score of 10 or below
Willingness to provide informed consent
Ability to read and communicate in English (with corrected vision and hearing, if needed)

Exclusion:

Meets DSM 5 criteria for Minor or Major Neurocognitive Disorder
Any other lifetime DSM 5 diagnosis except for simple/specific phobias
Significant neurological condition (e.g., stroke, seizure disorder, MS)
Unstable medical illness, (e.g., uncontrolled diabetes mellitus or hypertension)
Participants taking anticonvulsants, and other psychotropic medication (see exception below) that cannot be safely tapered and discontinued. The following psychotropic medications are allowed if they have been taken at a stable dose for at least 4 weeks: zopiclone up to 15 mg/day; trazadone up to 150 mg/day; benzodiazepine at a dose of up to 3 mg/day lorazepam-equivalents; gabapentin and pregabalin (if prescribed for pain).
A pace-maker or other metal implants
Neuropsychological testing within the past 12 months

Sites / Locations

Baycrest Centre for Geriatric Care
Centre for Addiction and Mental Health
St. Michael's Hospital
Sunnybrook Heath Sciences Centre
University Health Network

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Sham Comparator

Arm Label

tDCS + CR

sham tDCS + sham CR

Arm Description

Intervention sessions are administered 5 days/week for 8 weeks (induction phase). Then, for 5 days every 6 months (consolidation phase).Transcranial Direct Current Stimulation (tDCS) session: anode over Fz & cathode over Iz; direct current: 2 mA (current density=0.57A/m2) for 30 minutes/session at the beginning of each group session. Cognitive Remediation (CR) will also be administered. Sessions last 2 hours each day in a group supervised by trained interventionists. Participants also complete CR exercises online at home. CR consists of computer-based exercises relevant to attention, processing speed, executive function, and verbal and working memory with titrated difficulty levels. Performance feedback will reinforce progress. "Strategic monitoring and bridging discussions" promotes transfer of cognitive gains to everyday tasks. During COVID-19, booster sessions can be provided either in-person or virtually (except for tDCS that cannot be done remotely).

First, the intervention sessions will be administered 5 days/week for 8 weeks (induction phase). Then, for 5 days once every 6 months (consolidation phase). tDCS session: anode over Fz & cathode over Iz; direct current: 2 mA (current density=0.57A/m2) for 1 minute, then the current will be 0 mA for 29 minutes at the beginning of each group session. Cognitive Remediation (CR) will also be administered. Sessions last 2 hours each day in a group supervised by trained interventionists. Participants will also complete CR exercises online at home. CR will consist of computer-based exercises relevant to attention, processing speed, executive function, and verbal and working memory without titrated difficulty levels. During COVID-19, booster sessions can be provided either in-person or virtually (except for sham tDCS that cannot be done remotely).

Outcomes

Primary Outcome Measures

Change in cognitive scores over time

Z-scores for 18 measures of 12 selected cognitive tests will be calculated based on an healthy comparison group; based on these measures, in turn, z-scores will be averaged into six z-scores for six cognitive domains (executive functioning, language, speed of processing, verbal memory, visual memory, and working memory); finally, the six domain z-scores will be averaged into a composite cognitive score, the change of which is the study primary outcome measure that will be used for H1 and H3.

Secondary Outcome Measures

Percentage of subjects who remain free of MCI or dementia over time

Based on consensus conference diagnosis made according to DSM-5

Full Information

NCT ID

NCT02386670

First Posted

February 27, 2015

Last Updated

April 20, 2021

Sponsor

Centre for Addiction and Mental Health

Collaborators

Brain Canada, Applied Health Research Centre, Queen's University, Baycrest Centre for Geriatric Care, Unity Health Toronto, Sunnybrook Health Sciences Centre, University Health Network, Toronto

1. Study Identification

Unique Protocol Identification Number

NCT02386670

Brief Title

Prevention of Alzheimer's Disease With CR Plus tDCS in Mild Cognitive Impairment and Depression (PACt-MD)

Acronym

PACt-MD

Official Title

Prevention of Alzheimer's Dimentia With Cognitive Remediation Plus Transcranial Direct Current Stimulation in Mild Cognitive Impairment and Depression

Study Type

Interventional

2. Study Status

Record Verification Date

April 2021

Overall Recruitment Status

Unknown status

Study Start Date

January 2015 (Actual)

Primary Completion Date

June 2022 (Anticipated)

Study Completion Date

December 2022 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title

Principal Investigator

Name of the Sponsor

Centre for Addiction and Mental Health

Collaborators

Brain Canada, Applied Health Research Centre, Queen's University, Baycrest Centre for Geriatric Care, Unity Health Toronto, Sunnybrook Health Sciences Centre, University Health Network, Toronto

4. Oversight

Data Monitoring Committee

Yes

5. Study Description

Brief Summary

This 7-year randomized controlled trial will compare the efficacy of non-invasive brain stimulation (trans-cranial Direct Current Stimulation - tDCS) combined with cognitive remediation (CR) versus sham ("placebo") tDCS combined with sham ("placebo") CR in slowing down cognitive decline and preventing Alzheimer's Dementia in older persons with mild cognitive impairment or major depressive disorder with or without mild cognitive impairment.

Detailed Description

By the time Alzheimer's Dementia (AD) and related disorders (ADRD) are diagnosed the brain has sustained substantial insult that limits the efficacy of current treatments. Preventive interventions are urgently needed but prevention studies require large numbers of participants and long follow-up periods unless they can target a high-risk population. The investigators propose to study the efficacy of a preventive intervention for AD in three high risk groups: (1) older persons with Mild Cognitive Impairment (MCI); (2) older persons with a major depressive disorder (MDD) without MCI; and (3) older persons with MDD and MCI. MCI is considered a prodromal condition for dementia with a progression rate of about 1% per month. MDD has independently been identified as one of the most promising targets for AD prevention studies since, even after successful treatment of their depressive episode, older persons with remitted MDD develop MCI or dementia at a rate of 1-2% per month. The investigators proposed intervention is a combination of cognitive remediation (CR) and non-invasive brain stimulation - transcranial Direct Current Stimulation (tDCS). Participants with MCI or MDD (with or without MCI) will be randomized to tDCS + CR or sham ("palcebo") tDCS + sham ("placebo") CR. Both CR and tDCS have been shown to induce neuroplasticity and improve cognition. The investigators hypothesize that their combination will enhance cognitive reserve and protect against cognitive decline and the onset of MCI in those with "normal" cognition or AD in those with MCI. The investigators design is informed by their experience conducting randomized controlled trials (RCTs) in older participants with dementia, MCI, or MDD over more than two decades. In the investigators recent donepezil prevention trial, combining donepezil with standard antidepressant maintenance prevented cognitive decline and the incidence of dementia in participants who had had both MDD and MCI. Building on this prevention trial, the investigators conceptualize the proposed study as a high-risk, high-gain RCT aimed at enhancing cognitive reserve and preventing cognitive decline and dementia in a high risk population. If the investigators are successful in this high risk population, then tDCS + CR can be tested in, and extended to, the general population (i.e., for universal prevention) or other groups at high risk for AD (i.e., for selective or indicated prevention). Five Toronto academic sites with a history of successful collaboration will consent up to a total of 500 participants meeting criteria for MCI (age 60 and older) or MDD (age 65 and older) to reach a target of 375 enrolled participants initiating the study intervention. Participants will be randomized to either: i) tDCS + CR or ii) sham tDCS + sham CR. They will first receive tDCS + CR (or sham + sham) 5 days a week for 8 weeks, followed by home-based CR (or sham) and booster sessions of tDCS + CR (or sham + sham) for 5 days every 6 months until they develop dementia (or MCI for those who are deemed cognitively intact at baseline) or complete the study. During the COVID-19 pandemic, the study has been modified to be administered in a hybrid manner to accommodate both in-person and virtual assessments. Clinical and cognitive assessments (every 12 months) can be done in person or remotely (via telephone or using WebEx/Zoom). Some assessments are modified to accommodate the change in format of administration while maintaining the validity and integrity of the data. The assessments that cannot be done via phone or videoconference will temporarily not be done. Similarly, the intervention booster group sessions (every 6 months) can also be provided in two formats of in-person or virtual (via WebEx or Zoom) sessions. The tDCS administration cannot be done remotely and hence the virtual booster sessions will only consist of the CR exercises.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study

Mild Cognitive Impairment, Major Depressive Disorder, Recurrent, In Remission, Major Depressive Disorder, Single Episode, in Full Remission

7. Study Design

Primary Purpose

Prevention

Study Phase

Not Applicable

Interventional Study Model

Parallel Assignment

Masking

ParticipantInvestigatorOutcomes Assessor

Allocation

Randomized

Enrollment

375 (Actual)

8. Arms, Groups, and Interventions

Arm Title

tDCS + CR

Arm Type

Experimental

Arm Description

Arm Title

sham tDCS + sham CR

Arm Type

Sham Comparator

Arm Description

Intervention Type

Other

Intervention Name(s)

tDCS + CR

Other Intervention Name(s)

transcranial Direct Current Stimulation (tDCS), Cognitive Remediation (CR)

Intervention Description

First, the intervention sessions will be administered 5 days/week for 8 weeks (induction phase). Then, for 5 days once every 6 months (consolidation phase). tDCS session: anode over Fz & cathode over Iz; direct current: 2 mA (current density=0.57A/m2) for 30 min. at the beginning of each group session. Cognitive Remediation (CR) will also be administered. Sessions last 2 hours each day in a group supervised by trained interventionists. Participants will also complete CR exercises online at home. CR will consist of computer-based exercises relevant to attention, processing speed, executive function, and verbal and working memory with titrated difficulty levels. Performance feedback will reinforce progress. "Strategic monitoring and bridging discussions" will promote transfer of cognitive gains to everyday tasks. During COVID-19, booster sessions can be provided either in-person or virtually (except for tDCS that cannot be done remotely).

Intervention Type

Other

Intervention Name(s)

sham tDCS + sham CR

Intervention Description

Primary Outcome Measure Information:

Title

Change in cognitive scores over time

Description

Time Frame

Approximately 4, 12, 24, 36, 48, 60 months after baseline

Secondary Outcome Measure Information:

Title

Percentage of subjects who remain free of MCI or dementia over time

Description

Based on consensus conference diagnosis made according to DSM-5

Time Frame

Approximately 4, 12, 24, 36, 48, 60 months after baseline

10. Eligibility

Sex

All

Minimum Age & Unit of Time

60 Years

Accepts Healthy Volunteers

Eligibility Criteria

MCI Group Inclusion: Age > 60 (on day of randomization) DSM 5 criteria for Mild Neurocognitive Disorder ("MCI") Willingness to provide informed consent MADRS score of 10 or below Availability of a study partner who has regular contact with the participant Ability to read and communicate in English (with corrected vision and hearing, if needed) Exclusion: Met DSM 5 criteria for Major Depressive Episode in past 10 years Lifetime DSM 5 diagnosis of schizophrenia, bipolar disorder, or OCD DSM 5 diagnosis of alcohol or other substances use disorder within the past 12 months High risk for suicide Significant neurological condition (e.g., stroke, seizure disorder, MS) Unstable medical illness, (e.g., uncontrolled diabetes mellitus or hypertension) Having taken a cognitive enhancer (acetylcholinesterase inhibitor or memantine) within the past 6 weeks. Participants taking anticonvulsants, and other psychotropic medication (see exceptions below) that cannot be safely tapered and discontinued. The following psychotropic medications are allowed: i) any antidepressant; ii) zopiclone, trazadone, or a benzodiazepine if they have been taken at a stable dose for at least 4 weeks prior to study entry and; iii) gabapentin and pregabalin if they have been taken at a stable dose for at least 4 weeks prior to study entry AND if prescribed for chronic pain. A pace-maker or other metal implants that would preclude safe use of tDCS. MDD Group Inclusion: Age ≥ 65 (on day of randomization) Meets DSM 5 criteria for one or more MDE(s)with: an offset of 2 months to 5 years from the screening visit date. It is not necessary for this (these) episode(s) to have received medical attention OR an offset of 5 years or more from the screening visit date. It is necessary that at least one MDE received medical attention (e.g., previously been on one or more antidepressant(s), saw a psychiatrist, primary care physician, or had a previous hospitalization). Also, the MDE must have occurred during the participant's adult life (i.e., at 18 years of age or older). MADRS score of 10 or below Willingness to provide informed consent Availability of a study partner who has regular contact with the participant Ability to read and communicate in English (with corrected vision and hearing, if needed) Exclusion: Meets DSM 5 criteria for Major Neurocognitive Disorder ("dementia") Lifetime DSM 5 diagnosis of schizophrenia, bipolar disorder, or OCD DSM 5 diagnosis of alcohol or other substances use disorder within the past 12 months. High risk for suicide. Significant neurological condition (e.g., stroke, seizure disorder, MS) Unstable medical illness (e.g., uncontrolled diabetes mellitus or hypertension) Participants taking anticonvulsants, and other psychotropic medication (see exception below) that cannot be safely tapered and discontinued. In addition to any antidepressant, the following psychotropic medications are allowed if they have been taken at a stable dose for at least 4 weeks prior to study entry: zopiclone, trazodone, or a benzodiazepine; and gabapentin or pregabalin if prescribed for chronic pain. Having taken a cognitive enhancer (acetylcholinesterase inhibitor or memantine) within the past 6 weeks. A pace-maker or other metal implants that would preclude safe use of tDCS. Received electroconvulsive therapy (ECT) within 6 months of baseline neruopsychological testing. Control group Inclusion: Age > 60 MADRS score of 10 or below Willingness to provide informed consent Ability to read and communicate in English (with corrected vision and hearing, if needed) Exclusion: Meets DSM 5 criteria for Minor or Major Neurocognitive Disorder Any other lifetime DSM 5 diagnosis except for simple/specific phobias Significant neurological condition (e.g., stroke, seizure disorder, MS) Unstable medical illness, (e.g., uncontrolled diabetes mellitus or hypertension) Participants taking anticonvulsants, and other psychotropic medication (see exception below) that cannot be safely tapered and discontinued. The following psychotropic medications are allowed if they have been taken at a stable dose for at least 4 weeks: zopiclone up to 15 mg/day; trazadone up to 150 mg/day; benzodiazepine at a dose of up to 3 mg/day lorazepam-equivalents; gabapentin and pregabalin (if prescribed for pain). A pace-maker or other metal implants Neuropsychological testing within the past 12 months

Overall Study Officials:

First Name & Middle Initial & Last Name & Degree

Benoit H Mulsant, MD

Organizational Affiliation

Centre for Addiction and Mental Health

Official's Role

Principal Investigator

Facility Information:

Facility Name

Baycrest Centre for Geriatric Care

City

Toronto

State/Province

Ontario

Country

Canada

Facility Name

Centre for Addiction and Mental Health

City

Toronto

State/Province

Ontario

Country

Canada

Facility Name

St. Michael's Hospital

City

Toronto

State/Province

Ontario

Country

Canada

Facility Name

Sunnybrook Heath Sciences Centre

City

Toronto

State/Province

Ontario

Country

Canada

Facility Name

University Health Network

City

Toronto

State/Province

Ontario

Country

Canada

12. IPD Sharing Statement

Plan to Share IPD

Undecided

IPD Sharing Plan Description

Pending

Citations:

PubMed Identifier

34023224

Citation

Weinstein AM, Gujral S, Butters MA, Bowie CR, Fischer CE, Flint AJ, Herrmann N, Kennedy JL, Mah L, Ovaysikia S, Pollock BG, Rajji TK, Mulsant BH; PACt-MD Study Group.. Diagnostic Precision in the Detection of Mild Cognitive Impairment: A Comparison of Two Approaches. Am J Geriatr Psychiatry. 2022 Jan;30(1):54-64. doi: 10.1016/j.jagp.2021.04.004. Epub 2021 Apr 14.

Results Reference

derived

PubMed Identifier

33846084

Citation

Chandramouleeshwaran S, Ahsan N, Raymond R, Nobrega JN, Wang W, Fischer CE, Flint AJ, Herrmann N, Kumar S, Lanctot K, Mah L, Mulsant BH, Pollock BG, Rajji TK. Relationships Between a New Cultured Cell-Based Serum Anticholinergic Activity Assay and Anticholinergic Burden Scales or Cognitive Performance in Older Adults. Am J Geriatr Psychiatry. 2021 Dec;29(12):1239-1252. doi: 10.1016/j.jagp.2021.03.002. Epub 2021 Mar 18.

Results Reference

derived

PubMed Identifier

32323313

Citation

Dham P, Bingham KS, Bowie CR, Butters MA, Fischer CE, Flint A, Herrmann N, Kumar S, Mah L, Mulsant BH, Pollock BG, Rajji TK; for PACt-MD Study Group. Functional Competence and Cognition in Individuals With Amnestic Mild Cognitive Impairment. J Am Geriatr Soc. 2020 Aug;68(8):1787-1795. doi: 10.1111/jgs.16454. Epub 2020 Apr 22.

Results Reference

derived

Links:

URL

https://pubmed.ncbi.nlm.nih.gov/32568198/

Description

Rajji et al. 2020. Design and Rationale of the PACt-MD Randomized Clinical Trial: Prevention of Alzheimer's dementia with Cognitive remediation plus transcranial direct current stimulation in Mild cognitive impairment and Depression

URL

https://www.nature.com/articles/s41386-020-0759-z

Description

Brooks et al. 2020. Theta-gamma coupling and ordering information: a stable brain-behavior relationship across cognitive tasks and clinical conditions

URL

https://www.futuremedicine.com/doi/10.2217/nmt-2017-0021

Description

Liu et al. 2017. Using transcranial direct current stimulation to treat symptoms in mild cognitive impairment and Alzheimer's disease

URL

https://pubmed.ncbi.nlm.nih.gov/32109935/

Description

Neufeld et al. 2020. Structural brain networks in remitted psychotic depression

URL

https://www.frontiersin.org/articles/10.3389/fnagi.2018.00101/full

Description

Goodman et al. 2018. Theta-Gamma Coupling and Working Memory in Alzheimer's Dementia and Mild Cognitive Impairment

URL

https://pubmed.ncbi.nlm.nih.gov/30909240/

Description

Goodman et al. 2019. Changes in Theta but not Alpha Modulation Are Associated with Impairment in Working Memory in Alzheimer's Disease and Mild Cognitive Impairment

URL

https://pubmed.ncbi.nlm.nih.gov/30741676/

Description

Fischer et al. 2019. Examining the Link Between Cardiovascular Risk Factors and Neuropsychiatric Symptoms in Mild Cognitive Impairment and Major Depressive Disorder in Remission

URL

https://pubmed.ncbi.nlm.nih.gov/31104028/

Description

Yuen et al. 2019. Association between Sleep Disturbances and Medial Temporal Lobe Volume in Older Adults with Mild Cognitive Impairment Free of Lifetime History of Depression

URL

https://pubmed.ncbi.nlm.nih.gov/31270885/

Description

Brown et al. 2019. Brain Amyloid PET Tracer Delivery is Related to White Matter Integrity in Patients with Mild Cognitive Impairment

URL

https://www.nature.com/articles/s41386-020-0715-y

Description

Rashidi-Ranjbar et al. 2020. Frontal-executive and corticolimbic structural brain circuitry in older people with remitted depression, mild cognitive impairment, Alzheimer's dementia, and normal cognition

URL

https://pubmed.ncbi.nlm.nih.gov/33775259/

Description

Karameh et al. 2021. Comparing cardiovascular risk factors in older persons with mild cognitive impairment and lifetime history of major depressive disorder

Learn more about this trial

Prevention of Alzheimer's Disease With CR Plus tDCS in Mild Cognitive Impairment and Depression (PACt-MD)

We'll reach out to this number within 24 hrs